ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients with Moderate to Severe
Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone